United Kingdom

People: Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

5:22pm BST
Change (% chg)

$-0.70 (-1.75%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bancel, Stephane 

Mr. Stephane J. Bancel has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2013. He joined the Company's Supervisory Board as well as the Compensation Committee in 2013 and joined the Audit Committee and Science and Technology Committee in 2014. He is President and Founding Chief Executive Officer of Moderna Therapeutics, Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, which is advancing multiple drug development programs involving messenger RNA therapeutics. Before joining Moderna, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. Prior to bioMerieux, he was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis, Indiana, after having started at Lilly in Great Britain. Before joining Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMerieux while based in Tokyo, Japan. He holds a Master of Engineering degree from Ecole Centrale Paris (ECP), a Master of Science in Chemical Engineering from the University of Minnesota and an M.B.A. from Harvard Business School. He is Member of the Audit Committee, Member of the Compensation Committee, and Member of the Science and Technology Committee of the Company.

Basic Compensation

Total Annual Compensation, USD 89,500
Restricted Stock Award, USD 9,866
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 99,366

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --